Wall Street brokerages predict that Mersana Therapeutics Inc (NASDAQ:MRSN) will announce earnings of ($0.70) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Mersana Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.65). Mersana Therapeutics posted earnings per share of ($0.61) during the same quarter last year, which indicates a negative year-over-year growth rate of 14.8%. The company is expected to report its next earnings report on Wednesday, March 27th.
According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($2.52) per share for the current year, with EPS estimates ranging from ($2.57) to ($2.47). For the next financial year, analysts anticipate that the firm will post earnings of ($2.45) per share, with EPS estimates ranging from ($2.79) to ($1.93). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Tuesday, November 13th. The company reported ($0.75) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.16). Mersana Therapeutics had a negative return on equity of 110.44% and a negative net margin of 440.47%. The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $3.98 million.
In other Mersana Therapeutics news, insider Timothy B. Lowinger sold 3,500 shares of the business’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $11.63, for a total value of $40,705.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 39.70% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers purchased a new position in shares of Mersana Therapeutics in the second quarter worth $211,000. Schwab Charles Investment Management Inc. raised its stake in shares of Mersana Therapeutics by 20.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 24,500 shares of the company’s stock worth $438,000 after purchasing an additional 4,200 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Mersana Therapeutics by 27.4% in the second quarter. Bank of New York Mellon Corp now owns 31,615 shares of the company’s stock worth $564,000 after purchasing an additional 6,804 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of Mersana Therapeutics in the second quarter worth $776,000. Finally, Millennium Management LLC purchased a new position in shares of Mersana Therapeutics in the second quarter worth $2,198,000. Hedge funds and other institutional investors own 85.46% of the company’s stock.
Mersana Therapeutics stock traded up $0.09 during mid-day trading on Friday, hitting $5.31. The company had a trading volume of 54,400 shares, compared to its average volume of 136,625. Mersana Therapeutics has a 12 month low of $5.07 and a 12 month high of $23.96. The company has a market capitalization of $121.01 million, a price-to-earnings ratio of -1.63 and a beta of 1.10.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Featured Story: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.